-
公开(公告)号：US20240327888A1
公开(公告)日：2024-10-03
申请号：US18579664
申请日：2022-07-15
申请人： INBIOSE N.V.
CPC分类号： C12P19/26 , C12N9/1051 , C12N15/63 , C12Y204/01069
摘要： The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cells in a cultivation, preferably a fermentation. The present invention describes a cell and a method for production of a compound. The cell expresses an alpha-1,2-fucosyltransferase that has galactoside alpha-1,2-fucosyltransferase activity on the galactose residue of Gal-b1,3-GlcNAc (LNB, lacto-N-biose). Furthermore, the present invention provides for purification of said compound from the cultivation.
-
公开(公告)号：US20230265399A1
公开(公告)日：2023-08-24
申请号：US18040629
申请日：2021-08-10
申请人： INBIOSE N.V.
发明人： Sofie Aesaert , Joeri Beauprez , Pieter Coussement , Thomas Decoene , Nausicaä Lannoo , Gert Peters , Kristof Vandewalle , Annelies Vercauteren
CPC分类号： C12N9/1048 , C12N15/52 , C12Y204/00 , C12P19/18 , C12N5/00 , C12N1/00
摘要： The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of a mixture of at least four different neutral non-fucosylated oligosaccharides. Furthermore, the disclosure provides a method for the production of a mixture of at least four different neutral non-fucosylated oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation.
-
3.发明授权公开(公告)号：US10738336B2
公开(公告)日：2020-08-11
申请号：US15839264
申请日：2017-12-12
申请人： Inbiose N.V.
发明人： Joeri Beauprez , Gaspard Lequeux , Jo Maertens
摘要： The present invention relates to mutated and/or transformed microorganisms for the synthesis of various compounds. More specifically, the present invention discloses microorganisms mutated in the genes encoding for the regulators ArcA and IclR. The latter mutations result in a significant upregulation of the genes that are part of the colanic acid operon. Hence, said microorganisms are useful for the synthesis of any compound being part of the colanic acid pathway such as GDP-fucose, GDP-mannose and colanic acid, and/or, can be further used—starting form GDP-fucose as a precursor—to synthesize fucosylated oligosaccharides or—starting from GDP-mannose as a precursor—to synthesize mannosylated oligosaccharides. In addition, mutations in the genes coding for the transcriptional regulators ArcA and IclR lead to an acid resistance phenotype in the exponential growth phase allowing the synthesis of pH sensitive molecules or organic acids.
-
公开(公告)号：US20190338328A1
公开(公告)日：2019-11-07
申请号：US16473932
申请日：2017-12-26
申请人： INBIOSE N.V.
IPC分类号： C12P19/18 , C12P19/26 , C12N15/52 , C12N9/10 , C12N9/16 , C12N9/80 , C12N9/88 , C12N9/12 , C12N9/90
摘要： The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered microorganisms. The present invention describes engineered microorganisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These microorganisms can dephosphorylate N-acetylglucosamine-6-phosphate to N-acetylglucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These microorganisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate. Furthermore, the present invention provides a method for the large scale in vivo synthesis of sialylated compounds, by culturing a microorganism in a culture medium, optionally comprising an exogenous precursor such as, but not limited to lactose, lactoNbiose, N-acetyllactosamine and/or an aglycon, wherein said microorganism intracellularly dephosphorylates N-acetylglucosamine-6-phosphate to N-acetylglucosamine, converts N-acetylglucosamine to N-acetylmannosamine and convert the latter further to N-acetyl-neuraminate.
-
5.发明授权公开(公告)号：US09951362B2
公开(公告)日：2018-04-24
申请号：US15619377
申请日：2017-06-09
申请人： Inbiose N.V.
发明人： Joeri Beauprez , Gaspard Lequeux , Jo Maertens
摘要： The present invention relates to mutated and/or transformed microorganisms for the synthesis of various compounds. More specifically, the present invention discloses microorganisms mutated in the genes encoding for the regulators ArcA and IclR. The latter mutations result in a significant upregulation of the genes that are part of the colanic acid operon. Hence, said microorganisms are useful for the synthesis of any compound being part of the colanic acid pathway such as GDP-fucose, GDP-mannose and colanic acid, and/or, can be further used—starting form GDP-fucose as a precursor—to synthesize fucosylated oligosaccharides or—starting from GDP-mannose as a precursor—to synthesize mannosylated oligosaccharides. In addition, mutations in the genes coding for the transcriptional regulators ArcA and IclR lead to an acid resistance phenotype in the exponential growth phase allowing the synthesis of pH sensitive molecules or organic acids.
-
公开(公告)号：US20240191270A1
公开(公告)日：2024-06-13
申请号：US18555611
申请日：2022-04-15
申请人： INBIOSE N.V.
IPC分类号： C12P19/12 , C12N9/00 , C12N9/04 , C12N9/10 , C12N9/12 , C12N9/88 , C12N9/90 , C12N15/52 , C12P19/26
CPC分类号： C12P19/12 , C12N9/0006 , C12N9/1025 , C12N9/1048 , C12N9/1051 , C12N9/1085 , C12N9/1205 , C12N9/1241 , C12N9/88 , C12N9/90 , C12N9/93 , C12N15/52 , C12P19/26 , C12Y101/01271 , C12Y203/03009 , C12Y204/01038 , C12Y204/01069 , C12Y204/01152 , C12Y207/01006 , C12Y207/01052 , C12Y207/07023 , C12Y207/0703 , C12Y207/07043 , C12Y401/03001 , C12Y402/01047 , C12Y504/02008 , C12Y504/0201 , C12Y602/01001
摘要： The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cell in a cultivation, preferably a fermentation. The present invention describes a cell for the production of a compound. The cell comprises a pathway for the production of the compound, which can be a disaccharide, oligosaccharide and/or a Neu(n)Ac-containing bioproduct, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The cell is metabolically engineered for enhanced synthesis of acetyl-Coenzyme A. The invention also resides in a method of producing such compound by cultivation, preferably a fermentation, with such a cell.
-
公开(公告)号：US20240117398A1
公开(公告)日：2024-04-11
申请号：US18261806
申请日：2022-01-20
申请人： INBIOSE N.V.
IPC分类号： C12P19/26 , C07K14/195 , C12N9/10 , C12P19/18
CPC分类号： C12P19/26 , C07K14/195 , C12N9/1051 , C12P19/18
摘要： Described is a method of producing an oligosaccharide comprising a lacto-N-triose (LN3; GlcNAc-beta1,3-Gal-beta1,4-Glc) as a core trisaccharide by cultivation with a genetically modified cell, as well as the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for a galactoside beta-1,3-N-acetylglucosaminyltransferase and a glycosyltransferase involved in the synthesis of an oligosaccharide comprising LN3 as a core trisaccharide and at least one nucleic acid sequence expressing a membrane protein. Furthermore, the present invention provides for a purification of the oligosaccharide comprising LN3 as a core trisaccharide from the cultivation.
-
公开(公告)号：US11913046B2
公开(公告)日：2024-02-27
申请号：US17049814
申请日：2018-04-23
申请人： INBIOSE N.V.
CPC分类号： C12N9/88 , C12N1/20 , C12N9/0006 , C12N9/1051 , C12P19/18 , C12Y101/01 , C12Y204/01069 , C12Y402/01047
摘要： Microbial cells genetically engineered with a heterologous nucleic acid sequence that increases export of 2′ fucosyllactose are disclosed. Methods of increasing export of 2′ fucosyllactose from a microbial cell and for identifying a heterologous nucleic acid sequence that increases export of 2′ fucosyllactose from a microbial cell are also disclosed.
-
公开(公告)号：US20240035004A1
公开(公告)日：2024-02-01
申请号：US18254345
申请日：2021-12-17
申请人： INBIOSE N.V.
发明人： Joeri Beauprez , Katarzyna Ciesielska , Nausicaä Lannoo , Kristof Vandewalle , Annelies Vercauteren
CPC分类号： C12N9/1205 , C12N1/205 , C12Y207/01 , C12R2001/19
摘要： The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered cells. The present invention describes new sucrose permease polypeptides, and their applications. The present invention also describes a metabolically engineered cell for the production of a glycosylated product using the novel sucrose permease polypeptides. Furthermore, the present invention provides a method for the production of a glycosylated product by a cell using the novel sucrose permease polypeptides as well as the purification of said glycosylated product from the cultivation.
-
公开(公告)号：US20230406875A1
公开(公告)日：2023-12-21
申请号：US18247118
申请日：2021-09-28
申请人： INBIOSE N.V.
IPC分类号： C07H1/08 , C07H3/06 , A23L33/125 , A23L33/00
CPC分类号： C07H1/08 , C07H3/06 , A23L33/125 , A23L33/40
摘要： This specification relates to a process for preparing a purified human milk oligosaccharide (“HMO”) from an HMO-containing solution (e.g., a fermentation broth) by a process comprising mixed bed ion exchange, and a product of such a process.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.019 秒)
